Abstract
Background: Rheumatoid arthritis (RA) is a potentially devastating form of chronic arthritis. Methotrexate is the cornerstone of drug therapy of the disorder, and may slow or prevent joint damage. Unfortunately, this agent is not without adverse effects. Furthermore, increasing age has been been invoked as a predictor of greater toxicity and drug discontinuation by some, but not all, investigators.
Objective: To assess the effect of age and other covariates on methotrexate discontinuation in a population-based sample of older patients with newly diagnosed RA.
Methods: We studied the health administrative databases covering residents of the province of Québec, Canada. In these databases, we identified 246 individuals aged ≥65 years with newly diagnosed RA who had been started on methotrexate. We assessed discontinuation of methotrexate therapy using Cox proportional hazards regression models, with potential predictors of discontinuation being age, sex, co-morbidity, methotrexate dose and route (oral vs intramuscular), folic acid coadministration and disease severity.
Results: Five patients died or were lost to follow-up in the database at 6 months, and there were ten such patients at 1 year. Six months after the initial prescription of methotrexate therapy, about 80% (n = 192) of remaining subjects continued to be prescribed the drug. By 1 year, 161 of 236 (68.2%) subjects continued to be prescribed the drug; by 2 years, only 108 of 217 (49.8%) subjects continued to receive the drug. Increasing age was associated with a greater risk of methotrexate discontinuation.
Conclusion: Our population-based data indicate that increasing age is associated with a greater tendency for methotrexate discontinuation in patients with newly diagnosed RA. These results emphasize the need to ensure that older patients with RA are provided with effective therapy to minimize the effects of this chronic, potentially disabling disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hartzheim LA, Goss GL. Rheumatoid arthritis: a case study. Nurs Clin North Am 1998; 33(4): 595–602
Pincus T, Sokka T. How can the risk of long-term consequences of rheumatoid arthritis be reduced? Best Pract Res Clin Rheumatol 2001; 15(1): 139–70
Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford) 2007; 46(7): 1157–60
Potter T, Mulherin D, Pugh M, et al. Early intervention with disease-modifying therapy for rheumatoid arthritis: where do the delays occur? Rheumatology 2002; 41(8): 953–5
Emery P, Breedveld FC, Dougados M, et al. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 2002; 61(4): 290–7
Irvine S, Munro R, Porter D. Early referral, diagnosis, and treatment of rheumatoid arthritis: evidence for changing medical practice. Ann Rheum Dis 1999; 58(8): 510–3
McKendry RJ, Dale P. Adverse effects of low dose methotrexate therapy in rheumatoid arthritis. J Rheumatol 1993; 20(11): 1850–6
Tett SE, Triggs EJ. Use of methotrexate in older patients: a riskbenefit assessment. Drugs Aging 1996; 9(6): 458–71
Wolfe F, Hawley DJ, Cathey MA. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990; 17(8): 994–1002
Kaipiainen-Seppanen O, Aho K, Isomaki H, et al. Shift in the incidence of rheumatoid arthritis toward elderly patients in Finland during 1975–1990. Clin Exp Rheumatol 1996; 14(5): 537–42
Savolainen E, Kaipiainen-Seppanen O, Kroger L, et al. Total incidence and distribution of inflammatory joint diseases in a defined population: results from the Kuopio 2000 arthritis survey. J Rheumatol 2003; 30(11): 2460–8
Tutuncu Z, Reed G, Kremer J, et al. Do patients with older-onset rheumatoid arthritis receive less aggressive treatment? Ann Rheum Dis 2006; 65(9): 1226–9
Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40(5): 373–83
Treharne GJ, Lyons AC, Hale ED, et al. ‘Compliance’ is futile but is ‘concordance’ between rheumatology patients and health professionals attainable? Rheumatology (Oxford) 2006; 45(1): 1–5
Garber MC, Nau DP, Erickson SR, et al. The concordance of self-report with other measures of medication adherence: a summary of the literature. Med Care 2004; 42(7): 649–52
Mulherin D, Wong M. Drug survival in rheumatoid arthritis. Rheumatology (Oxford) 2006; 45(9): 1178–9
Wolfe F. The epidemiology of drug treatment failure in rheumatoid arthritis. Baillieres Clin Rheumatol 1995; 9(4): 619–32
Pincus T, Marcum SB, Callahan LF. Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol 1992; 19(12): 1885–94
Yazici Y, Sokka T, Kautiainen H, et al. Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities. Ann Rheum Dis 2005; 64(2): 207–11
Ortendahl M, Schettler JD, Fries JF. Factors influencing length of time taking methotrexate in rheumatoid arthritis. J Rheumatol 2000; 27(5): 1139–47
Maradit-Kremers H, Nicola PJ, Crowson CS, et al. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis. J Rheumatol 2006; 33(2): 248–55
Acknowledgements
The study was funded by the Canadian Institutes of Health Research (CIHR). Dr Ehrmann Feldman is supported by the Arthritis Society of Canada. Dr Bernatsky is the recipient of career awards from the CIHR, the Fonds de la recherché en santé de Québec and the Canadian Arthritis Network. The authors acknowledge the support of l’Agence de développement de réseaux locaux de services de santé et de services sociaux: Région de Montréal Santé Publique. The design, analysis, interpretation of data, writing of the report and decision to submit the paper for publication were independent of funding sources. The authors have no conflicts of interest that are directly relevant to the content of this study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bernatsky, S., Feldman, D.E. Discontinuation of Methotrexate Therapy in Older Patients with Newly Diagnosed Rheumatoid Arthritis. Drugs Aging 25, 879–884 (2008). https://doi.org/10.2165/00002512-200825100-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002512-200825100-00007